Quantitative analysis for Artiva Biotherapeutics, Inc. (ARTV) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Buy (60.0) (grade B). Gem alpha score: 66.0. 33 signals analyzed (27 differentiated alt-data).
ARTV stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-29 | $9.33 | $8.52 | $8.72 |
| 2026-05-11 | $11.68 | $10.43 | $10.60 |
| 2026-05-21 | $8.41 | $7.73 | $7.99 |
| 2026-06-03 | $7.44 | $6.71 | $6.97 |
| 2026-06-15 | $9.77 | $8.52 | $9.18 |
| 2026-06-26 | $9.66 | $8.80 | $9.62 |
| 2026-07-09 | $9.77 | $9.20 | $9.41 |
| 2026-07-21 | $10.06 | $9.04 | $10.00 |
| 2026-07-31 | $10.41 | $9.67 | $10.10 |
| 2026-08-12 | $12.10 | $11.51 | $11.53 |
| 2026-08-24 | $11.70 | $10.49 | $11.52 |
| 2026-09-03 | $11.35 | $10.98 | $11.13 |
How Artiva Biotherapeutics, Inc. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| IPSC | Century Therapeutics, Inc. | $195M | — |
| ACB | Aurora Cannabis Inc. | $197M | 35.0 |
| CRBU | Caribou Biosciences, Inc. | $198M | — |
| ALMR | Alamar Biosciences, Inc. | $189M | — |
View all Health Care stocks by valuation and signals →
Artiva Biotherapeutics, Inc. (ARTV) scores Buy (60.0), and the composite conceals a 90-point disagreement between its dimensions. It is strongest on ML forecast at 97 and AI Alpha (gem) at 96, and weakest on analyst consensus at 7. A stock can carry ML forecast that high while analyst consensus sits at 7; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| ML forecast | 97 |
| AI Alpha (gem) | 96 |
| competitive moat | 87 |
| earnings quality | 82 |
| valuation | 72 |
| technicals | 53 |
| analyst consensus | 7 |
StoQuant analyzes 33 signals (27 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on Artiva Biotherapeutics, Inc. (ARTV): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/ARTV"><img src="https://stoquant.com/badge/ARTV.svg" alt="Artiva Biotherapeutics, Inc. (ARTV) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.